Cargando…

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing

Understanding genetic aberrations in cancer leads to discovery of new targets for cancer therapies. The genomic landscape of hepatocellular carcinoma (HCC) has not been fully described. Therefore, patients with refractory advanced/metastatic HCC referred for experimental therapies, who had adequate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janku, Filip, Kaseb, Ahmed O., Tsimberidou, Apostolia M., Wolff, Robert A., Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102787/ https://www.ncbi.nlm.nih.gov/pubmed/24931142

Ejemplares similares

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience
por: Hou, Ming-Mo, et al.
Publicado: (2014)

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
por: Wheler, Jennifer J., et al.
Publicado: (2014)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2015)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses
por: Wheler, Jennifer, et al.
Publicado: (2013)

Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
por: Bang, Jieun, et al.
Publicado: (2023)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
por: Park, Haeseong, et al.
Publicado: (2016)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2013)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR
por: Maiese, Kenneth
Publicado: (2013)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
por: Reilly, R., et al.
Publicado: (2017)

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
por: Darici, Salihanur, et al.
Publicado: (2020)

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
por: Li, Huayi, et al.
Publicado: (2021)

A pilot study of temsirolimus and body composition
por: Veasey-Rodrigues, Heloisa, et al.
Publicado: (2013)

The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
por: Tian, Ling-Yu, et al.
Publicado: (2023)

Sequential Dosing in Chemosensitization: Targeting the PI3K/Akt/mTOR Pathway in Neuroblastoma
por: Westhoff, Mike-Andrew, et al.
Publicado: (2013)

Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
por: Barzegar Behrooz, Amir, et al.
Publicado: (2022)

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
por: Glaviano, Antonino, et al.
Publicado: (2023)

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
por: El-Osta, Hazem, et al.
Publicado: (2011)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Targeting PI3K/mTOR Signaling in Cancer
por: Arcaro, Alexandre
Publicado: (2014)

Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives
por: Bupathi, Manojkumar, et al.
Publicado: (2014)

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma
por: Bhatti, Maria, et al.
Publicado: (2018)

Targeting the PI3K/AKT/mTOR/NFκB Axis in Ovarian Cancer
por: Ghoneum, Alia, et al.
Publicado: (2020)

The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19
por: Basile, Maria Sofia, et al.
Publicado: (2022)

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
por: Li, Qingfang, et al.
Publicado: (2022)

Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape
por: Subbiah, Ishwaria M., et al.
Publicado: (2017)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer
por: Pavlidou, Athanasia, et al.
Publicado: (2014)

Computer-Aided Targeting of the PI3K/Akt/mTOR Pathway: Toxicity Reduction and Therapeutic Opportunities
por: Li, Tan, et al.
Publicado: (2014)

Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)
por: Tan, Aaron C.
Publicado: (2020)

Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients
por: Abu-Eid, Rasha, et al.
Publicado: (2021)

BSCI-11. Targeting PI3K/Akt/mTOR pathway to prevent melanoma brain metastasis
por: Tehranian, Cedric, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8pvor1qqno666o3773bhbs4a4n